Camurus Past Earnings Performance
Past criteria checks 2/6
Camurus has been growing earnings at an average annual rate of 71.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 45.3% per year. Camurus's return on equity is 8.6%, and it has net margins of 15.8%.
Key information
71.8%
Earnings growth rate
72.6%
EPS growth rate
Pharmaceuticals Industry Growth | 30.5% |
Revenue growth rate | 45.3% |
Return on equity | 8.6% |
Net Margin | 15.8% |
Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark
Dec 07Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality
Nov 15Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 10What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You
Aug 09Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Jul 19We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
Jul 12Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders
May 02Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
Apr 19Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Feb 22With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case
Feb 17Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected
Dec 20Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues
Nov 11We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve
Feb 22Revenue & Expenses Breakdown
How Camurus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,689 | 266 | 531 | 746 |
30 Jun 24 | 1,593 | 223 | 497 | 731 |
31 Mar 24 | 1,823 | 450 | 449 | 718 |
31 Dec 23 | 1,717 | 431 | 424 | 638 |
30 Sep 23 | 1,610 | 460 | 383 | 543 |
30 Jun 23 | 1,468 | 408 | 356 | 502 |
31 Mar 23 | 1,020 | 115 | 330 | 457 |
31 Dec 22 | 956 | 56 | 309 | 474 |
30 Sep 22 | 871 | 28 | 289 | 445 |
30 Jun 22 | 784 | -13 | 268 | 422 |
31 Mar 22 | 695 | -69 | 249 | 423 |
31 Dec 21 | 601 | -90 | 240 | 389 |
30 Sep 21 | 523 | -142 | 275 | 355 |
30 Jun 21 | 470 | -156 | 285 | 319 |
31 Mar 21 | 413 | -128 | 275 | 252 |
31 Dec 20 | 336 | -167 | 269 | 239 |
30 Sep 20 | 265 | -174 | 214 | 229 |
30 Jun 20 | 205 | -216 | 197 | 246 |
31 Mar 20 | 136 | -284 | 198 | 263 |
31 Dec 19 | 106 | -290 | 194 | 249 |
30 Sep 19 | 78 | -305 | 192 | 248 |
30 Jun 19 | 58 | -286 | 168 | 235 |
31 Mar 19 | 53 | -266 | 145 | 225 |
31 Dec 18 | 49 | -235 | 123 | 208 |
30 Sep 18 | 47 | -200 | 100 | 194 |
30 Jun 18 | 40 | -208 | 93 | 205 |
31 Mar 18 | 52 | -187 | 80 | 206 |
31 Dec 17 | 54 | -191 | 72 | 223 |
30 Sep 17 | 86 | -166 | 64 | 234 |
30 Jun 17 | 104 | -127 | 55 | 209 |
31 Mar 17 | 111 | -102 | 49 | 191 |
31 Dec 16 | 114 | -81 | 43 | 172 |
30 Sep 16 | 113 | -85 | 29 | 154 |
30 Jun 16 | 120 | -95 | 26 | 156 |
31 Mar 16 | 116 | -189 | 31 | 151 |
31 Dec 15 | 155 | -160 | 31 | 153 |
30 Sep 15 | 263 | -53 | 42 | 153 |
31 Dec 14 | 208 | 48 | 34 | 114 |
31 Dec 13 | 198 | 99 | 22 | 53 |
Quality Earnings: CAMX has high quality earnings.
Growing Profit Margin: CAMX's current net profit margins (15.8%) are lower than last year (28.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAMX has become profitable over the past 5 years, growing earnings by 71.8% per year.
Accelerating Growth: CAMX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CAMX had negative earnings growth (-42.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).
Return on Equity
High ROE: CAMX's Return on Equity (8.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 02:12 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Oscar Haffen Lamm | Bryan Garnier & Co |
Alexandru Cogut | Bryan Garnier & Co |
Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |